The translation factor eIF4E is a key mediator of doxorubicin resistance: insights from a triple-negative breast cancer model.

ABSTRACT: Triple-negative breast cancer (TNBC) tumors are highly aggressive and typically associated with poor prognosis due to limited therapeutic options and significant chemoresistance. This study investigated the role of the translation initiation factor eIF4E in doxorubicin (Dox) resistance using a novel TNBC model. A doxorubicin-resistant cell variant, MDA_R (IC₅₀ = 1.8 µM), was derived from MDA-MB-231 cells (IC₅₀ = 0.6 µM) following prolonged exposure to Dox at its IC₂₅ concentration. Compared to the parental line, MDA_R cells exhibited enhanced migration, invasion, and drug efflux capabilities. Dox treatment sustained the phosphorylation of eIF4E at Ser209 (eIF4E-p^Ser209), which promoted activation of the VEGF pathway and secret

SUBMITTER: Frayde-Gomez H 

PROVIDER: S-EPMC12804909 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature